Stockscreener 앱 받기
3.82
5.21%
-0.21
시장 영업 전:
3.88
0.06
+1.57%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last? - Yahoo Finance
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics (IOVA) reports Q1 loss, lags revenue estimates - MSN
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Iovance Shareholders Approve Expanded Capital Flexibility and Governance - TipRanks
Iovance (NASDAQ: IOVA) gains Australian Amtagvi approval as shareholders back larger share pool - Stock Titan
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001 - Insider Monkey
IOVA: All proposals passed; strong growth, robust pipeline, and focus on revenue and margin improvement - TradingView
Iovance Biotherapeutics: Progress With Caveats (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (IOVA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Iovance rises as Australia approves melanoma therapy Amtagvi - MSN
IOVANCE (NASDAQ: IOVA) interim CEO reports RSU vesting and tax-share withholding - Stock Titan
IOVANCE (IOVA) Chief Medical Officer logs RSU vesting, tax-withheld shares in Form 4 - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax share withholding - Stock Titan
IOVANCE (NASDAQ: IOVA) COO RSUs vest; 3,976 shares withheld for tax - Stock Titan
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance’s Amtagvi® (lifileucel) receives approval for treatment of Advanced Melanoma in Australia - BioSpectrum Asia
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption - Yahoo Finance
Iovance Biotherapeutics (IOVA) Sees Revenue Surge 45% on Amtagvi Growth Despite Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi - Yahoo Finance
Iovance Biotherapeutics (IOVA) Slides 3.4% as Biotech Sector Faces Renewed PressureSmart Money Flow Stocks - newsline.com
Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential? - Insider Monkey
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now? - Insider Monkey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Australia approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com Nigeria
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
5 Stocks Crushing the Market With Surging Returns - Insider Monkey
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15% - Insider Monkey
IOVA: AMTAGVI’s rapid growth and strong clinical data drive expansion, with pivotal trials and new therapies advancing - TradingView
Iovance Biotherapeutics (IOVA) Secures Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance wins Australian nod for melanoma drug (IOVA:NASDAQ) - Seeking Alpha
Australia approves Iovance’s Amtagvi for advanced melanoma - Investing.com Australia
Iovance’s Amtagvi granted Australian approval - The Pharma Letter
Iovance Biotherapeutics (IOVA) Receives Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance stock gains after Australia approves melanoma therapy - Investing.com
Iovance stock gains after Australia approves melanoma therapy By Investing.com - Investing.com India
1.27%
1.43%
자본화:
|
볼륨(24시간):